Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
RESEARCH TOOLSreports
Holding ARQT?
Track your performance easily
ARQT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.76 - $13.17
Previous Close$10.18
Volume206.24K
Average Volume (3M)2.03M
Market Cap
$1.20B
Enterprise Value$1.06B
Total Cash (Recent Filing)$330.56M
Total Debt (Recent Filing)$208.18M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Mar 04, 2025EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.79
Shares Outstanding117,044,591
10 Day Avg. Volume2,571,131
30 Day Avg. Volume2,026,566
Standard Deviation0.27
R-Squared0.05
Alpha0.00375
Financial Highlights & Ratios
Price to Book (P/B)7.60
Price to Sales (P/S)8.51
Price to Cash Flow (P/CF)-8.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.63
Enterprise Value/Gross Profit19.38
Enterprise Value/Ebitda-6.04
Forecast
1Y Price Target
$18.00Price Target Upside73.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Arcutis Biotherapeutics News
PremiumCompany Announcements
Arcutis Biotherapeutics Reports Strong Q3 2024 Results
Bulls Say, Bears Say
Bulls Say
Market LeadershipZoryve is currently the leader in branded anti-inflammatory topical class, addressing the 4.5M commercially insured PsO, seb derm, and AD patients.
Prescription GrowthZoryve Foam 0.3% showed significant growth with a 9.4% increase in total prescriptions and 6.9% increase in new prescriptions.
Sales PerformanceZoryve franchise sales of $44.5MM exceeded consensus by 20%, driven by strong volume growth.
Bears Say
Market PerformanceRecent prescription growth was previously hindered by adverse weather conditions, affecting market performance.
Prescription DeclineVTAMA experienced a decrease of 6.4% in total prescriptions and a slight decrease of 0.3% in new prescriptions.
Product PerformanceZoryve Cream 0.3% for plaque psoriasis saw a decline in total prescriptions by 6.6%.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ARQT FAQ
What was Arcutis Biotherapeutics’s price range in the past 12 months?
Arcutis Biotherapeutics lowest stock price was $1.76 and its highest was $13.17 in the past 12 months.
What is Arcutis Biotherapeutics’s market cap?
Currently, no data Available
When is Arcutis Biotherapeutics’s upcoming earnings report date?
Arcutis Biotherapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 103 days.
How were Arcutis Biotherapeutics’s earnings last quarter?
Arcutis Biotherapeutics released its earnings results on Nov 06, 2024. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.417 by $0.087.
Is Arcutis Biotherapeutics overvalued?
According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued.
Does Arcutis Biotherapeutics pay dividends?
Arcutis Biotherapeutics does not currently pay dividends.
What is Arcutis Biotherapeutics’s EPS estimate?
Arcutis Biotherapeutics’s EPS estimate is -$0.28.
How many shares outstanding does Arcutis Biotherapeutics have?
Arcutis Biotherapeutics has 117,044,590 shares outstanding.
What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?
Arcutis Biotherapeutics reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.417. Following the earnings report the stock price went up 7.66%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics?
Among the largest hedge funds holding Arcutis Biotherapeutics’s share is Gilder Gagnon Howe & Co LLC.. It holds Arcutis Biotherapeutics’s shares valued at 33M.
---
Arcutis Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.00 (73.41% Upside)
$18.00 (73.41% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 295.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
391.78%
12-Months-Change
Fundamentals
Return on Equity
-192.31%
Trailing 12-Months
Asset Growth
49.29%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
---
ARQT Company Deck
---
ARQT Earnings Call
Q3 2024
0:00 / 0:00
---
ARQT Stock 12 Month Forecast
Average Price Target
$18.00
▲(73.41% Upside)
Technical Analysis
Best Analysts Covering ARQT
1 Year
1 Year Success Rate
6/18 ratings generated profit
1 Year Average Return
+16.47%
reiterated a buy rating 15 days ago
Copying Vikram Purohit's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +16.47% per trade.
---